[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340629-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340629-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","chd1l-inhibitor-oti-611-synergizes-with-chemotherapy-to-enhance-antitumor-efficacy-and-prolong-survival-in-colorectal-cancer-mouse-models","CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models","","Colorectal cancer (CRC) is treated with DNA-damaging chemotherapy, typically irinotecan, 5-fluorouracil (5-FU), and oxaliplatin, yet resistance limits long-term benefit. CHD1L is an oncogene controlling chromatin remodeling and DNA damage repair and thereby regulating malignant gene expression. An inhibitor of CHD1L, OTI-611, increases DNA damage in CRC cell lines and synergizes with SN-38, 5-FU, and oxaliplatin in tumor organoids. OTI-611 traps CHD1L, PARP1, and PARP2 on chromatin, disrupts PAR-chain protection, and drives CHD1L-mediated PARthanatos via nuclear AIF translocation. Low-dose OTI-611 plus irinotecan reduces tumor volume and prolongs survival in CRC xenograft models, supporting CHD1L-targeted combination therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/chd1l-inhibitor-oti-611-synergizes-with-chemotherapy-to-enhance-antitumor-efficacy-and-prolong-survival-in-colorectal-cancer-mouse-models/340629/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/chd1l-inhibitor-oti-611-synergizes-with-chemotherapy-to-enhance-antitumor-efficacy-and-prolong-survival-in-colorectal-cancer-mouse-models/340629.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does OTI-611 play in colorectal cancer treatment?","Question",{"text":63,"@type":64},"OTI-611 inhibits CHD1L. It increases DNA damage in CRC cell lines and shows synergistic killing when combined with standard chemotherapies and SN-38 in tumor organoids.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does OTI-611 induce cell death mechanistically?",{"text":68,"@type":64},"OTI-611 traps CHD1L, PARP1, and PARP2 on chromatin, leading to nuclear PAR-chain deprotection. This triggers CHD1L-mediated PARthanatos, evidenced by AIF translocation to the nucleus.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports improved outcomes in vivo?",{"text":72,"@type":64},"In CRC xenograft mouse models, combining low doses of OTI-611 with irinotecan significantly reduces tumor volume and extends survival compared with irinotecan alone.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340629,1790147571,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nCHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models  \nRita Sala 1,†, Hector Esquer 1,2,3,†, Timothy Kellett 1, Sophia Clune 1, Paul Awolade 1,2, Laura A. Pike 1, Qiong Zhou 1,2,3, Wells A. Messersmith 2,3,4 and Daniel V. LaBarbera 1,2,3, *  \nCitation: Sala, R.; Esquer, H.; Kellett, T.; Clune, S.; Awolade, P.; Pike, L.A.; Zhou, Q.; Messersmith, W.A.; LaBarbera, D.V. CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models. Int.  \nJ. Mol. Sci. 2024, 25, 13160. [https://](https://)[ ](https://)[doi.org/10.3390/ijms252313160](doi.org/10.3390/ijms252313160)  \n1 Department of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, The University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA  \n2 The CU Anschutz Center for Drug Discovery, Aurora, CO 80045, USA  \n3 The University of Colorado Cancer Center, Aurora, CO 80045, USA  \n4 Division of Medical Oncology, The School of Medicine, The University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA  \n* Correspondence: [daniel.labarbera@cuanschutz.edu](daniel.labarbera@cuanschutz.edu)[ ](daniel.labarbera@cuanschutz.edu)† These authors contributed equally to this work.  \nAbstract: Colorectal cancer (CRC) is one of the most prevalent and deadly forms of cancer. It is universally treated with a combination of the DNA damaging chemotherapy drugs irinotecan, 5-Fluorouracil (5-FU), and oxaliplatin. CHD1L is a novel oncogene that plays critical roles in chromatin remodeling and DNA damage repair, as well as the regulation of malignant gene expression. We show that an inhibitor of CHD1L, OTI-611, when combined with chemotherapy significantly increases DNA damage in CRC cell lines. OTI-611 also synergizes with SN-38, 5-FU, and oxaliplatinin killing CRC tumor organoids. We also demonstrate that, as in breast cancer, OTI-611 traps CHD1L, PARP1, and PARP2 onto chromatin. The entrapment of CHD1L causes the deprotection of PAR chains in the nucleus, ultimately resulting in cell death by CHD1Li-mediated PARthanatos, as measured by AIF translocation to the nucleus. Finally, the combination of low doses of OTI-611 with irinotecan significantly reduces tumor volume and extends survival in CRC xenograft mouse models compared toirinotecan alone. The combination of standard of care chemotherapy drugs with CHD1Li represents a promising advancement in future therapeutic strategies for CRC and other cancers driven by CHD1L.  \nKeywords: CHD1L; CHD1L inhibitor (CHD1Li); colorectal cancer; cancer; DNA damage response; PARthanatos; cancer drug combinations; chemotherapy; cancer pharmacology  \n1. Introduction  \nAcademic Editor: Carmine Stolfi  \nReceived: 2 November 2024  \nRevised: 22 November 2024  \nAccepted: 2 December 2024  \nPublished: 7 December 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nColorectal cancer (CRC) is the third most diagnosed cancer each year and the second leading cause of cancer-related deaths worldwide, with metastasis being the primary cause of mortality [1,2] . Despite progress in prevention strategies that have lowered CRC incidence and mortality, nearly a quarter of patients are still diagnosed at an advanced or metastatic stage, where the 5-year survival rate is just 13%[2,3] . Chemotherapy, which typically includes a combination of irinotecan, 5-fluorouracil (5-FU), and oxaliplatin, is a standard of care (SOC) treatment for CRC and is expected to remain so for the foreseeable future [4–6] . However, only about 50% of patients initially respond to che","cbCaidKztn5Ja6HV","https://ap.wps.com/l/cbCaidKztn5Ja6HV","pdf",5113492,18,"English","# Introduction\n## Chemotherapy and resistance mechanisms\n## CHD1L biology and PARthanatos","[{\"question\":\"What role does OTI-611 play in colorectal cancer treatment?\",\"answer\":\"OTI-611 inhibits CHD1L. It increases DNA damage in CRC cell lines and shows synergistic killing when combined with standard chemotherapies and SN-38 in tumor organoids.\"},{\"question\":\"How does OTI-611 induce cell death mechanistically?\",\"answer\":\"OTI-611 traps CHD1L, PARP1, and PARP2 on chromatin, leading to nuclear PAR-chain deprotection. This triggers CHD1L-mediated PARthanatos, evidenced by AIF translocation to the nucleus.\"},{\"question\":\"What evidence supports improved outcomes in vivo?\",\"answer\":\"In CRC xenograft mouse models, combining low doses of OTI-611 with irinotecan significantly reduces tumor volume and extends survival compared with irinotecan alone.\"}]","CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models | PDF",1790037789,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83680b541afd7eead13e8357ca8f7260.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e709f996092256219283bca07971c568.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/100bd68cdb3b41b56cfd23a31fdfa0c9.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa7849bd839c4f5fae91ce13c64c860d.webp",980,1385]